reMYND's CRO announces quarterly digital Newsletter
08-02-2011
The prestigious Journal of Alzheimer's Disease publishes new data on reMYND's proprietary mouse models of Alzheimer's disease.
Read more
Review in Nature highlights reMYND's discovery platform
15-11-2010
The growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases was featured in Nature Reviews Drug Discovery.
Read more
reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
08-09-2010

New data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing.

Read more
reMYND and Amorfix announce agreement
06-07-2010
Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND nv today announced the signing of a partnership agreement.
Read more
Ablynx and reMYND settle dispute amicably
02-06-2010
Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement.
Read more
reMYND receives a grant of 0.9 million EUR from IWT
10-12-2009
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND receives license renewal from Schering-Plough for RadarScreen
18-11-2009
reMYND nv announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough.
Read more
reMYND receives award for Company with an exceptional relevance to society
21-09-2009
reMYND received 'the 1st Award for Company with an exceptional relevance to society'.
Read more
reMYND awarded by the Michael J. Fox Foundation
21-07-2009
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation
Read more
reMYND receives a grant of almost 1 million EUR from IWT
10-12-2008
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more